Evidence map›Paper›PMID 39796016›Full record

ArticleInternational journal of molecular sciences2024

Two Novel Mouse Models of Duchenne Muscular Dystrophy with Similar Dmd Exon 51 Frameshift Mutations and Varied Phenotype Severity.

Iuliia P Baikova, Leonid A Ilchuk, Polina D Safonova, Ekaterina A Varlamova, Yulia D Okulova, Marina V Kubekina, Anna V Tvorogova, Daria M Dolmatova, Zanda V Bakaeva, Evgenia N Kislukhina and 3 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Iuliia P BaikovaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia.ORCID 0000-0002-1901-3640
Leonid A IlchukCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia.ORCID 0000-0002-0157-2102
Polina D SafonovaCore Facility Center, Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia.
Ekaterina A VarlamovaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia.ORCID 0000-0002-8451-1216
Yulia D OkulovaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia.
Marina V KubekinaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia.
Anna V TvorogovaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia.
Daria M DolmatovaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia.ORCID 0000-0002-8396-2672
Zanda V BakaevaNational Medical Research Center of Children's Health, 119296 Moscow, Russia.ORCID 0000-0002-2797-3270
Evgenia N KislukhinaNational Medical Research Center of Children's Health, 119296 Moscow, Russia.ORCID 0000-0001-9217-1330
Natalia V LizunovaNational Medical Research Center of Children's Health, 119296 Moscow, Russia.ORCID 0000-0002-6644-7716
Alexandra V BruterCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia.
Yulia Yu SilaevaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia.

Funding

Ministry of Science and Higher Education of the Russian Federation 075-15-2019-1661
6 · The paper itself

Abstract

Duchenne muscular dystrophy (DMD) is a severe X-linked genetic disorder caused by an array of mutations in the dystrophin gene, with the most commonly mutated regions being exons 48-55. One of the several existing approaches to treat DMD is gene therapy, based on alternative splicing and mutant exon skipping. Testing of such therapy requires animal models that carry mutations homologous to those found in human patients. Here, we report the generation of two genetically modified mouse lines, named "insT" and "insG", with distinct mutations at the same position in exon 51 that lead to a frameshift, presumably causing protein truncation. Hemizygous males of both lines exhibit classical signs of muscular dystrophy in all muscle tissues except for the cardiac tissue. However, pathological changes are more pronounced in one of the lines. Membrane localization of the protein is reduced to the point of absence in one of the lines. Moreover, an increase in full-length isoform mRNA was detected in diaphragms of insG line mice. Although further work is needed to qualify these mutations as sole origins of dissimilarity, both genetically modified mouse lines are suitable models of DMD and can be used to test gene therapy based on alternative splicing.

Indexed as

Disease Models, AnimalDystrophinFrameshift MutationMuscular Dystrophy, DuchenneAnimalsExonsFemaleHomozygoteMaleMiceMice, TransgenicMuscle, SkeletalMutationMyocardiumRNA, MessengerSeverity of Illness IndexDmd protein, mouseDystrophinRNA, Messengeranimal modelDuchenne muscular dystrophydystrophingene therapy

Identifiers

PMID39796016
PMCPMC11719507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.